The biotech firm’s earnings exceeded expectations by $0.31, while revenue missed estimates by $10M for the quarter.
Argenx reported a GAAP earnings per share of $5.52, surpassing estimates by $0.31. The result reflects stronger-than-expected profitability amid ongoing operational execution.
Revenue reached $1.3 billion, missing consensus by $10M. The shortfall follows a prior quarter where revenue aligned closely with projections, though growth trends remain under scrutiny.
Shares showed limited immediate reaction as investors weigh the earnings beat against the revenue miss.